Trial Filter
BETAAn intelligent search tool for clinical trials
Official Title
A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma
Phase
Phase 1
Sponsor
Nammi Therapeutics Inc
Enrollment
100
Timeline
Aug 2024 → May 2028
About This Study
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conducted in two major parts which are further organized into two sub-parts. Part A Dose Escalation is a modified 3+3 with the first two cohorts consisting of one subject each based on the low clinical starting dose. Dose escalation in solid tumors (Part A1) will be followed by dose finding in multiple myeloma (Part A2). Part B consists of dose expansion in solid tumors (Part B1) and multiple myeloma (Part B2) using the recommended dose for expansion from Part A
Eligibility Criteria
Inclusion Criteria
- 1Participants with Solid Tumors
- 2Histopathologically confirmed diagnosis of an advanced, unresectable, or metastatic solid tumor (ovarian, pancreatic, urothelial, renal, hepatocellular, gastrointestinal (GI), lung, prostate, and breast cancer).
- 3Have progressed despite standard therapies, or for whom conventional therapy is not effective or tolerable, as judged by the Investigator. Patients must have no available therapeutic options known to confer clinical benefit for their tumor type.
- 4Participants with Multiple Myeloma
- 5Have progressed despite standard therapies, or for whom conventional therapy is not effective or tolerable, as judged by the Investigator.
- 6Patients must have failed at least 3 prior therapies for myeloma and should have had prior exposure to a proteosome inhibitor, an IMiD, and an anti-CD38-directed therapy.
- 72\. Male or female participants ≥18 years of age at the time of informed consent 3. An Eastern Cooperative Oncology Group (ECOG) performance status scale of 0, 1, or 2 at Screening 4. Must have at least 1 measurable lesion by RECIST version 1.1 (solid tumors only), or evaluable disease by IMWG Uniform Response Criteria (multiple myeloma only) 5. Adequate organ function and bone marrow reserve 6. Adequate cardiac function as estimated by left ventricular ejection fraction 7. Female participants of child-bearing potential must:
- 8Have a negative serum pregnancy test at screening and a negative pregnancy test at Week 1 Day 1 prior to first dose of QXL138AM, AND
- 9Agree to use at least 1 highly effective method of contraception for the duration of study participation, and for 120 days after last dose of QXL138AM.
- 108\. Male participants of child-bearing potential must:
- 11Agree to use at least 1 highly effective method of contraception for the duration of study participation, and for 120 days after last dose of QXL138AM, AND
- 12Refrain from sperm donation prior to the first dose of investigational product through 120 days following the last dose of QXL138AM.
Exclusion Criteria
- 1New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, a history of risk factors for Torsades de Pointes (TdP), including heart failure, hypokalemia, and family history of long QTc syndrome, or evidence of ischemia on ECG.
- 2Symptomatic ischemic heart disease or unstable angina pectoris; or history of cardiac angioplasty, cardiac stenting, or coronary artery bypass graft. A clinically significant baseline prolongation of QT/QTcF interval at screening.
- 3The use of concomitant medications that may significantly prolong the QT/QTc interval.
- 4Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.
- 5Known hypersensitivity to the investigational product or components (anti-CD138 IgG1 antibody, Interferon A2a and/or the formulation excipients: histidine, sucrose, arginine, polysorbate 80).
- 6Female participant is lactating.
- 7Any other clinically significant comorbidities.
- 8Received prior anticancer therapy within 28 days or 5x the half-life (whichever is shorter) prior to the first dose of investigational product.
- 9Participants who received wide-field radiation therapy within 4 weeks prior to first dose of investigational product, (2 weeks for limited field radiation therapy)
- 10Major surgery within 30 days before first dose of investigational product
- 11Chronic use of systemic corticosteroids of more than 20 mg/day of prednisone or equivalent.
- 12Active, clinically significant liver disease such as Hepatitis B or C, autoimmune hepatitis, or cirrhosis (Child Hugh Stage B or C).
- 13Current or history of mood disorder such as major depression per DSM-5 within past two years not controlled with current therapy.
- 14Active autoimmune disorders not controlled with current therapy.
- 15Active endocrine disorders including hypothyroidism, hyperthyroidism, hypoglycemia, hyperglycemia, and diabetes mellitus not controlled with current therapy.
Locations
8 sites participating in this study
Emory University - Winship Cancer Institute
Atlanta, Georgia 30322
Fatemeh Ardeshir, MD
University of Southern California
Los Angeles, California 90033
Anthony El-Khoueiry, MD
Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer
Los Angeles, California 90048
Kamya Sankar, MD
Data sourced from ClinicalTrials.govView on ClinicalTrials.gov →